Tonghe Pharmaceutical: Announcement on Obtaining Invention Patent Certificate

Securities code: 300636 Securities abbreviation: Tonghe Pharmaceutical Announcement number: 2025-050

Jiangxi Tonghe Pharmaceutical Co., Ltd.

Announcement on Obtaining Invention Patent Certificate

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and

Complete, without false records, misleading statements or material omissions.

Jiangxi Tonghe Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the invention patent certificate issued by the State Intellectual Property Office. The details are as follows:

Invention title: A Resmetirom intermediate and its preparation method and the preparation method of Intermediate III

Patent number: ZL 2023 1 1118581.4

Patent type: invention patent

Patent application date: 2023.09.01

Authorization announcement date: 2025.09.19

Patentee: Jiangxi Tonghe Pharmaceutical Co., Ltd.

The invention relates to the company's product Resmetirom. Resmetirol is a THRB agonist clinically used to treat non-alcoholic steatohepatitis and cirrhosis. The invention provides an intermediate compound of rismetirosin and a preparation method thereof, as well as a method for preparing the key intermediate compound of rismetiroxin III. The application of the new intermediate compound can significantly reduce the production cost and production cycle of the key intermediate compound of rismetiroxin III.

The acquisition of the above-mentioned invention patents will not have a significant impact on the company's recent production and operations, but it will help strengthen the company's independent intellectual property technology advantages and improve the intellectual property protection system, thereby enhancing the company's core competitiveness.

Announcement is hereby made.

Board of Directors of Jiangxi Tonghe Pharmaceutical Co., Ltd. September 19, 2025

1/1